QGEN Stock Analysis: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$44.07
-0.83 (-1.85%)
▼
5d:
+2.61%
30d:
+6.32%
90d:
+26.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: QGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: QGEN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$54.47
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$33.82
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $44.07, which is considered extended relative to its 30-day fair value range of $41.02 to $43.25. The stock's valuation (Forward PE: 17.2) is in line with its historical norms (15.9). At these levels, the market is pricing in 2.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, QGEN is in a uptrend. Immediate support is located at $42.14, while resistance sits at $45.53.
Market Sentiment: QGEN scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QGEN is in a uptrend. Immediate support is located at $42.14, while resistance sits at $45.53.
Market Sentiment: QGEN scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$41.02 -
$43.25
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
24.8%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (22/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($46.07)
- NEUTRAL: Market pricing in 2.7% annual earnings growth - fairly valued
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$41.02 -
$43.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$42.14
Resistance Level
$45.53
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.21
Wall Street Target
$46.07
(+2.6%)
Revenue Growth (YoY)
0.3%
Earnings Growth (YoY)
13.6%
Profit Margin
19.5%
Valuation Premium vs History
+2.7% premium
PE vs Historical
17.2 vs 15.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.7%
(market-implied from PE analysis)
1-Year Target
$46.11
(+3%)
2-Year Target
$47.36
(+6%)
3-Year Target
$48.64
(+8%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$44.95
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 7.2%)
$64.57
(+44%)
Base:
(SPY PE: 17.2, Growth: 7.2%)
$55.36
(+23%)
Bear:
(PE: 14.6, Growth: 7.2%)
$47.05
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 21.50 | Current EPS (TTM): $2.07
Bull Case
$61.71
(+40%)
Analyst growth 26.1%, PE expands to 23.7
Base Case
$56.10
(+27%)
Market implied 26.1%, PE stable at 21.5
Bear Case
$30.26
(-31%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 11:08 PM ET
Data refreshes hourly during market hours. Next update: 12:08 AM
Data refreshes hourly during market hours. Next update: 12:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$631 | 41 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 50 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 43 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$331 | 38 SELL |
